Keywords

• Enasidenib
• AG-221
• high purity and best price

Quick Details

• ProName: Enasidenib
• CasNo: 1446502-11-9
• Molecular Formula: 1446502-11-9
• Appearance: white powder
• Application: For laboratory use only- not intended ...
• ProductionCapacity: 1 Kilogram/Week
• Purity: ≥99%
• Storage: room temperature
• Transportation: by air
• LimitNum: 1 Gram

Superiority

Details

Enasidenib is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes. IC50 & Target: IDH2. In Vitro: Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3^ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b⁺ population and a decrease in the c-Kit⁺ population in the peripheral blood at 2wks. In Vivo: Treatment with Enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10mg/kg or 100mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2^R140QFlt3^ITD AML cells markedly reduces 2-hydroxyglutarate (2-HG) levels consistent with on target inhibition. Enasidenib inhibits mutant IDH2-mediated 2-HG production